Ezetimibe ketone
Code | Size | Price |
---|
TAR-T11251-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T11251-500mg | 500mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Images
Documents
Further Information
Bioactivity:
Ezetimibe, a compound known as a Niemann-Pick C1-like1 (NPC1L1) inhibitor and a potent Nrf2 activator, effectively inhibits cholesterol absorption. Additionally, Ezetimibe ketone (EZM-K) represents a phase-I metabolite of Ezetimibe.
CAS:
191330-56-0
Formula:
C24H19F2NO3
Molecular Weight:
407.41
Pathway:
Membrane transporter/Ion channel|Immunology/Inflammation
Purity:
0.98
SMILES:
C(CC(=O)C1=CC=C(F)C=C1)[C@@H]2[C@](N(C2=O)C3=CC=C(F)C=C3)(C4=CC=C(O)C=C4)[H]
Target:
Nrf2|NPC1L1
References
Yijun Zhu, et al. Efficient and scalable process for the synthesis of antihypercholesterolemic drug ezetimibe. Synthetic Communications. 2016, 46:20, 1687-1693.
Chang E, et al. Ezetimibe improves hepatic steatosis in relation to autophagy in obese and diabetic rats. World J Gastroenterol. 2015 Jul 7;21(25):7754-63.
Lee DH, et al. Ezetimibe, an NPC1L1 inhibitor, is a potent Nrf2 activator that protects mice from diet-induced nonalcoholic steatohepatitis. Free Radic Biol Med. 2016 Sep 12;99:520-532.